Sanofi Price To Sales vs. Current Valuation
| SNYN Stock | MXN 991.38 27.38 2.84% |
For Sanofi profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sanofi to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sanofi utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sanofi's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sanofi over time as well as its relative position and ranking within its peers.
Sanofi |
Sanofi Current Valuation vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sanofi's current stock value. Our valuation model uses many indicators to compare Sanofi value to that of its competitors to determine the firm's financial worth. Sanofi is rated below average in price to sales category among its peers. It is rated below average in current valuation category among its peers reporting about 51,049,469,882 of Current Valuation per Price To Sales. Comparative valuation analysis is a catch-all model that can be used if you cannot value Sanofi by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sanofi's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sanofi Current Valuation vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Sanofi |
| = | 52.71 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Sanofi |
| = | 2.69 T |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Sanofi Current Valuation vs Competition
Sanofi is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers - Major industry is at this time estimated at about 30.88 Trillion. Sanofi holds roughly 2.69 Trillion in current valuation claiming about 9% of equities under Drug Manufacturers - Major industry.
Sanofi Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sanofi, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sanofi will eventually generate negative long term returns. The profitability progress is the general direction of Sanofi's change in net profit over the period of time. It can combine multiple indicators of Sanofi, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. SANOFI is traded on Mexico Stock Exchange in Mexico.
Sanofi Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sanofi. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sanofi position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sanofi's important profitability drivers and their relationship over time.
Use Sanofi in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sanofi position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sanofi will appreciate offsetting losses from the drop in the long position's value.Sanofi Pair Trading
Sanofi Pair Trading Analysis
The ability to find closely correlated positions to Sanofi could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sanofi when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sanofi - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sanofi to buy it.
The correlation of Sanofi is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sanofi moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sanofi moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sanofi can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sanofi position
In addition to having Sanofi in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Gainers Thematic Idea Now
Latest Gainers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 142 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Sanofi Stock Analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.